Dr Reddy's launches psoriasis drug Sernivo in US

Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, Dr Reddy’s Laboratories has launched Sernivo (betamethasone dipropionate) spray, 0.05%, in the US. Sernivo spray, a topical steroid approved by the US Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
 
“We are proud to bring Sernivo spray to patients across the US. This is another significant milestone for Promius Pharma. As an emerging leader in the dermatology space, we are committed to developing innovative treatment options,” said Raghav Chari, executive vice president, proprietary products group at Dr Reddy’s Laboratories.
   
Promius Pharma’s current R&D pipeline and commercialised products address the needs of patients with dermatological and neurological conditions.